<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365572</url>
  </required_header>
  <id_info>
    <org_study_id>AN09049-004</org_study_id>
    <nct_id>NCT01365572</nct_id>
  </id_info>
  <brief_title>New Generation Drug Eluting Stent for In-stent Restenosis of Drug Eluting Stent( RESTENT-ISR Trial )</brief_title>
  <acronym>Restenosis</acronym>
  <official_title>Prospective, Single-blinded, Randomized Comparison of the Clinical and Angiographic Results With Intravascular Analysis of EverolimuS-Eluting Versus ZoTarolimus-Eluting steNTs for In-Stent Restenosis(ISR) Lesions: Volumetric Analysis With Intravascular Ultrasound(IVUS) : Phase IV Multicenter Trial ( RESTENT-ISR Trial )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catholic Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KangWon National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kunyang University Medical center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyemyeong Univerisity Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kwandong Univerisity Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kwangjoo Veteran Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dankook University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daegoo Catholic Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bucheon Sejong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Busan University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunkyungwan Univeristy Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Suncheonyang University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yongnam University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonkwang University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje Univerisity Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility, safety, and effectiveness of&#xD;
      EndeavorTM ResoluteTM and Xience VTM stent implantation in patients with restenosis following&#xD;
      drug-eluting stent (DES) implantation. The investigators will evaluate clinical, angiographic&#xD;
      and intravascular ultrasound (IVUS) assessment of 9-month efficacy of EndeavorTM ResoluteTM&#xD;
      or Xience VTM implantation in DES restenosis and assess the vascular changes of re-treatment&#xD;
      with DES for DES restenosis using follow-up IVUS analysis. In addition, the investigators&#xD;
      will evaluate the effectiveness of retreatment with EndeavorTM ResoluteTM or Xience VTM stent&#xD;
      implantation in patients with restenosis after DES&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent neointimal volume index</measure>
    <time_frame>9 months on IVUS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety end-point; to evaluate the procedural success and the incidence of 12-month death, MI, target-vessel failure (TVF), or stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy end-point</measure>
    <time_frame>9 months</time_frame>
    <description>Efficacy end-point; to evaluate the 9-month binary angiographic restenosis (â‰¥50 percent in-stent diameter stenosis) and late loss, vascular remodeling during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>In-stent Arterial Restenosis</condition>
  <arm_group>
    <arm_group_label>Xience V, drug-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized implantation for DES restenotic lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor Resolute, drug-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized implantation for DES restenotic lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xiene V stent, Endeavor Resolute stent</intervention_name>
    <description>for each lesion, randomized either Xience V stent or Endeavor Resolute stent</description>
    <arm_group_label>Endeavor Resolute, drug-eluting stent</arm_group_label>
    <arm_group_label>Xience V, drug-eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In-stent restenosis (over 50% by quantitative angiographic analysis) following all&#xD;
             types of DES; only insegment restenotic lesions without ISR are not included&#xD;
&#xD;
          -  Evidence of myocardial ischemia due to restenosis (e.g., stable, unstable angina,&#xD;
             recent infarction, silent ischemia, positive functional study or a reversible changes&#xD;
             in the ECG with or without ischemia) or over 70% by quantitative angiographic analysis&#xD;
&#xD;
          -  Repeat revascularization, needed with another stent (single stent implanted lesion,&#xD;
             lesion length no more than 28mm )&#xD;
&#xD;
          -  IVUS available lesions&#xD;
&#xD;
          -  Non-emergent conditions&#xD;
&#xD;
          -  Patients confirmed about study enrollment and 9 month followup angiogram and IVUS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Lesion &amp; Procedural exclusion criteria&#xD;
&#xD;
          -  IVUS unavailable lesion&#xD;
&#xD;
          -  Restenotic lesions following PCI of de novo lesion like as below;&#xD;
&#xD;
               -  left main lesions&#xD;
&#xD;
               -  BMS restenotic lesion&#xD;
&#xD;
               -  vein graft lesion&#xD;
&#xD;
          -  Restenotic lesions following 2.25mm DES implantation&#xD;
&#xD;
          -  Prior history of repeat DES implantation for DES restenosis (only conventional or&#xD;
             cutting ballooning treatment for DES restenosis is included in this study)&#xD;
&#xD;
          -  Simultaneous implantation of different types of DES on restenotic or another de novo&#xD;
             lesions (Only same DES implantation is allowed on the restenotic or another de novo&#xD;
             lesions)&#xD;
&#xD;
          -  Patients with little possibility of performing follow-up angiogram and IVUS&#xD;
&#xD;
        General exclusion criteria&#xD;
&#xD;
          -  Contraindication to anti-platelet agents &amp; Bleeding history within prior 3 months&#xD;
&#xD;
          -  Prior history or current presentation of DES thrombosis&#xD;
&#xD;
          -  Age over 80 years&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to any of the following medications:&#xD;
             Heparin, Aspirin, Clopidogrel, Zotarolimus, Everolimus&#xD;
&#xD;
          -  Severe hepatic dysfunction (3 times normal reference values)&#xD;
&#xD;
          -  Serum creatinine level over 2.0 mg/dL or end-stage renal diseases on dialysis&#xD;
&#xD;
          -  LVEF less than 30%&#xD;
&#xD;
          -  Pregnant women or women with potential childbearing&#xD;
&#xD;
          -  An elective surgical procedure is planned that would necessitate interruption of&#xD;
             clopidogrel during the first 9 months&#xD;
&#xD;
          -  Life expectancy 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Korea University Anam Hospital Ahn, MD, PhD</last_name>
    <phone>+82-2-920-5445</phone>
    <email>drcello@kumc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yousei Universty Healthcare System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yangsoo Jang, MD, PhD</last_name>
      <phone>+82-2228-8321</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <last_update_submitted>June 2, 2011</last_update_submitted>
  <last_update_submitted_qc>June 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Do-Sun Lim/ Interventional Cardiology Cardiovascular Center,</name_title>
    <organization>Korea University Anam Hospital</organization>
  </responsible_party>
  <keyword>Drug-eluting stent</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

